Preclinical development of 2ND generation HIV maturation inhibitors
Ended Project Grant Awarded Last action
- Award ID
- R42AI155312
- Recipient
-
DFH Pharma, Inc. UEI ZS2FYG92ALX3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,791,836
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $1,367,460.00 Federal
- $424,376.00 Non-federal
- Place of performance
- Gaithersburg, MD 20886, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $424,376 | $0 | |
| Amendment | $424,376 | $424,376 | |
| Original award | $518,708 | $0 |
Quick answers
Who received award R42AI155312?
R42AI155312 was awarded to DFH Pharma, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 8, 2020.
How much is award R42AI155312 worth?
$1,791,836 has been obligated on R42AI155312: $1,367,460 in federal funding and $424,376 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award